The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.
This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...
Coventry City are unbeaten across their past four home league games against Bristol City (W2 D2), since a 3-1 loss in October ...